• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10.

作者信息

Nyström Thomas, Bodegård Johan, Nathanson David, Thuresson Marcus, Norhammar Anna, Eriksson Jan W

机构信息

Unit for Diabetes Research, Division of Internal Medicine, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden.

AstraZeneca Nordic-Baltic, Södertälje, Sweden

出版信息

Diabetes Care. 2018 Jun;41(6):e104-e105. doi: 10.2337/dc18-0339.

DOI:10.2337/dc18-0339
PMID:29784707
Abstract
摘要

相似文献

1
Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10.
Diabetes Care. 2018 Jun;41(6):e104-e105. doi: 10.2337/dc18-0339.
2
Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10.
Diabetes Care. 2018 Jun;41(6):e106-e108. doi: 10.2337/dc18-0338.
3
Response to Comment on Suissa. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? Diabetes Care 2018;41:6-10.
Diabetes Care. 2018 Jun;41(6):e109-e110. doi: 10.2337/dci18-0015.
4
Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?在观察性研究中，SGLT2 抑制剂降低死亡风险：真实还是偏差？
Diabetes Care. 2018 Jan;41(1):6-10. doi: 10.2337/dc17-1223.
5
Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.SGLT2抑制剂的最新进展——美国糖尿病协会发布的新数据
Crit Pathw Cardiol. 2017 Sep;16(3):93-95. doi: 10.1097/HPC.0000000000000125.
6
SGLT2 inhibitors for diabetes: turning symptoms into therapy.用于治疗糖尿病的钠-葡萄糖协同转运蛋白2抑制剂：变症状为疗法。
Lancet. 2013 Sep 14;382(9896):917-8. doi: 10.1016/S0140-6736(13)60902-2. Epub 2013 Jul 12.
7
Comment on "Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D)".关于“卡格列净、钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂与非SGLT2抑制剂对2型糖尿病患者心力衰竭住院风险和截肢风险的比较疗效：4个观察性数据库的真实世界荟萃分析（OBSERVE-4D）”的评论
Diabetes Obes Metab. 2019 Feb;21(2):444-445. doi: 10.1111/dom.13509. Epub 2018 Sep 20.
8
Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.评估 2 型糖尿病女性患者在使用钠-葡萄糖共转运蛋白 2 抑制剂坎格列净治疗后的外阴阴道症状和假丝酵母菌定植情况。
Curr Med Res Opin. 2012 Jul;28(7):1173-8. doi: 10.1185/03007995.2012.697053. Epub 2012 Jun 14.
9
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.卡格列净，一种钠-葡萄糖协同转运蛋白2抑制剂，用于治疗2型糖尿病。
Hosp Pract (1995). 2014 Aug;42(3):96-108. doi: 10.3810/hp.2014.08.1122.
10
SGLT2 inhibitors-induced electrolyte abnormalities: An analysis of the associated mechanisms.钠-葡萄糖协同转运蛋白2抑制剂诱导的电解质异常：相关机制分析
Diabetes Metab Syndr. 2018 Jan-Mar;12(1):59-63. doi: 10.1016/j.dsx.2017.08.003. Epub 2017 Aug 11.

引用本文的文献

1
Observational research on sodium glucose co-transporter-2 inhibitors: A real breakthrough?钠-葡萄糖共转运蛋白 2 抑制剂的观察性研究：真正的突破？
Diabetes Obes Metab. 2018 Dec;20(12):2711-2723. doi: 10.1111/dom.13468. Epub 2018 Aug 14.